TrialSafety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
Trial details
- Registry ID
- NCT04475432
- Phase
- Phase 2, Phase 3
TARS
Tarsus Pharmaceuticals, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
8Trials in this database
4Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceTrial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
Trial details
- Registry ID
- NCT04784091
- Phase
- Phase 3
A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05
Trial details
- Registry ID
- NCT05387083
- Phase
- Phase 2
Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD
Trial details
- Registry ID
- NCT05454956
- Phase
- Phase 2
Study of TP-04 in Participants With Papulopustular Rosacea
Trial details
- Registry ID
- NCT05838170
- Phase
- Phase 2
Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex
Trial details
- Registry ID
- NCT06054217
- Phase
- Phase 2
Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)
Trial details
- Registry ID
- NCT07443202
- Phase
- Phase 2
A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
Trial details
- Registry ID
- NCT07562087
- Phase
- Phase 2
Latest recorded trial changes
A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
NCT07562087 · Tarsus Pharmaceuticals, Inc.
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
700 participants (planned)
+ After
722 participants (actual)
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD
NCT05454956 · Tarsus Pharmaceuticals, Inc.
Actual enrollment decreased by 1 participants
− Before
40 participants (actual)
+ After
39 participants (actual)